Global Nanomaterial-Based Adjuvants Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 87

Published Date: 09 Oct 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.

According to our (Global Info Research) latest study, the global Nanomaterial-Based Adjuvants Vaccine market size was valued at US$ 311590 million in 2023 and is forecast to a readjusted size of USD 576890 million by 2030 with a CAGR of 9.4% during review period.

Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Technological advancements in nanomaterial-based adjuvants vaccines are an important factor driving market development. Nano-adjuvants have the advantages of good biocompatibility, biological targeting, sustained release, safety and high efficiency, and can significantly improve the immunogenicity and protective effect of vaccines. With the continuous development and application of nanotechnology, the types and performance of nanomaterial-based adjuvants vaccines will be further improved to meet the needs of more disease prevention. As the market continues to expand and potential competitors join, competition in the nanomaterial-based adjuvants vaccines market will become more intense. Overall, the nanomaterial-based adjuvants vaccines market has broad prospects. With the advancement of technology and the increase in market demand, the market size is expected to continue to grow in the next few years.

This report is a detailed and comprehensive analysis for global Nanomaterial-Based Adjuvants Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030
Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030
Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2019-2030
Global Nanomaterial-Based Adjuvants Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (M Doses), and ASP (US$/Dose), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Nanomaterial-Based Adjuvants Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Nanomaterial-Based Adjuvants Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna, Jiangsu Recbio Technology, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Nanomaterial-Based Adjuvants Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Aluminium Hydroxides
    Aluminium Phosphate
    Lipidosome
    Others

Market segment by Application
    Pneumococcus
    Human Papilloma Virus
    DTaP
    Viral Hepatitis TypeA
    Viral Hepatitis TypeB
    SARS-CoV-2
    Others

Major players covered
    Emergent BioSolutions
    Sanofi
    GlaxoSmithKline Biologicals
    Merck
    Pfizer
    Novartis
    Moderna
    Jiangsu Recbio Technology

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nanomaterial-Based Adjuvants Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Nanomaterial-Based Adjuvants Vaccine, with price, sales quantity, revenue, and global market share of Nanomaterial-Based Adjuvants Vaccine from 2019 to 2024.
Chapter 3, the Nanomaterial-Based Adjuvants Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nanomaterial-Based Adjuvants Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Nanomaterial-Based Adjuvants Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Nanomaterial-Based Adjuvants Vaccine.
Chapter 14 and 15, to describe Nanomaterial-Based Adjuvants Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Aluminium Hydroxides
        1.3.3 Aluminium Phosphate
        1.3.4 Lipidosome
        1.3.5 Others
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Pneumococcus
        1.4.3 Human Papilloma Virus
        1.4.4 DTaP
        1.4.5 Viral Hepatitis TypeA
        1.4.6 Viral Hepatitis TypeB
        1.4.7 SARS-CoV-2
        1.4.8 Others
    1.5 Global Nanomaterial-Based Adjuvants Vaccine Market Size & Forecast
        1.5.1 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity (2019-2030)
        1.5.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Emergent BioSolutions
        2.1.1 Emergent BioSolutions Details
        2.1.2 Emergent BioSolutions Major Business
        2.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Emergent BioSolutions Recent Developments/Updates
    2.2 Sanofi
        2.2.1 Sanofi Details
        2.2.2 Sanofi Major Business
        2.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Sanofi Recent Developments/Updates
    2.3 GlaxoSmithKline Biologicals
        2.3.1 GlaxoSmithKline Biologicals Details
        2.3.2 GlaxoSmithKline Biologicals Major Business
        2.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates
    2.4 Merck
        2.4.1 Merck Details
        2.4.2 Merck Major Business
        2.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Merck Recent Developments/Updates
    2.5 Pfizer
        2.5.1 Pfizer Details
        2.5.2 Pfizer Major Business
        2.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Pfizer Recent Developments/Updates
    2.6 Novartis
        2.6.1 Novartis Details
        2.6.2 Novartis Major Business
        2.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Novartis Recent Developments/Updates
    2.7 Moderna
        2.7.1 Moderna Details
        2.7.2 Moderna Major Business
        2.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Moderna Recent Developments/Updates
    2.8 Jiangsu Recbio Technology
        2.8.1 Jiangsu Recbio Technology Details
        2.8.2 Jiangsu Recbio Technology Major Business
        2.8.3 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product and Services
        2.8.4 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Jiangsu Recbio Technology Recent Developments/Updates

3 Competitive Environment: Nanomaterial-Based Adjuvants Vaccine by Manufacturer
    3.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturer (2019-2024)
    3.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Nanomaterial-Based Adjuvants Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Nanomaterial-Based Adjuvants Vaccine Manufacturer Market Share in 2023
        3.4.3 Top 6 Nanomaterial-Based Adjuvants Vaccine Manufacturer Market Share in 2023
    3.5 Nanomaterial-Based Adjuvants Vaccine Market: Overall Company Footprint Analysis
        3.5.1 Nanomaterial-Based Adjuvants Vaccine Market: Region Footprint
        3.5.2 Nanomaterial-Based Adjuvants Vaccine Market: Company Product Type Footprint
        3.5.3 Nanomaterial-Based Adjuvants Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region
        4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2019-2030)
        4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2030)
        4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2019-2030)
    4.2 North America Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
    4.3 Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
    4.4 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
    4.5 South America Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)
    4.6 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
    5.2 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type (2019-2030)
    5.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
    6.2 Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application (2019-2030)
    6.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2030)

7 North America
    7.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
    7.2 North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
    7.3 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
        7.3.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
        7.3.2 North America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
    8.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
    8.3 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country
        8.3.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
        8.3.2 Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region
        9.3.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 South Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
    10.2 South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
    10.3 South America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
        10.3.1 South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
        10.3.2 South America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country
        11.3.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Nanomaterial-Based Adjuvants Vaccine Market Drivers
    12.2 Nanomaterial-Based Adjuvants Vaccine Market Restraints
    12.3 Nanomaterial-Based Adjuvants Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Nanomaterial-Based Adjuvants Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Nanomaterial-Based Adjuvants Vaccine
    13.3 Nanomaterial-Based Adjuvants Vaccine Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Nanomaterial-Based Adjuvants Vaccine Typical Distributors
    14.3 Nanomaterial-Based Adjuvants Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Emergent BioSolutions Basic Information, Manufacturing Base and Competitors
 Table 4. Emergent BioSolutions Major Business
 Table 5. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 6. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 7. Emergent BioSolutions Recent Developments/Updates
 Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
 Table 9. Sanofi Major Business
 Table 10. Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 11. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 12. Sanofi Recent Developments/Updates
 Table 13. GlaxoSmithKline Biologicals Basic Information, Manufacturing Base and Competitors
 Table 14. GlaxoSmithKline Biologicals Major Business
 Table 15. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 16. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 17. GlaxoSmithKline Biologicals Recent Developments/Updates
 Table 18. Merck Basic Information, Manufacturing Base and Competitors
 Table 19. Merck Major Business
 Table 20. Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 21. Merck Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 22. Merck Recent Developments/Updates
 Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
 Table 24. Pfizer Major Business
 Table 25. Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 26. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 27. Pfizer Recent Developments/Updates
 Table 28. Novartis Basic Information, Manufacturing Base and Competitors
 Table 29. Novartis Major Business
 Table 30. Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 31. Novartis Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 32. Novartis Recent Developments/Updates
 Table 33. Moderna Basic Information, Manufacturing Base and Competitors
 Table 34. Moderna Major Business
 Table 35. Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 36. Moderna Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 37. Moderna Recent Developments/Updates
 Table 38. Jiangsu Recbio Technology Basic Information, Manufacturing Base and Competitors
 Table 39. Jiangsu Recbio Technology Major Business
 Table 40. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product and Services
 Table 41. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales Quantity (M Doses), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 42. Jiangsu Recbio Technology Recent Developments/Updates
 Table 43. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Manufacturer (2019-2024) & (M Doses)
 Table 44. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturer (2019-2024) & (USD Million)
 Table 45. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturer (2019-2024) & (US$/Dose)
 Table 46. Market Position of Manufacturers in Nanomaterial-Based Adjuvants Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 47. Head Office and Nanomaterial-Based Adjuvants Vaccine Production Site of Key Manufacturer
 Table 48. Nanomaterial-Based Adjuvants Vaccine Market: Company Product Type Footprint
 Table 49. Nanomaterial-Based Adjuvants Vaccine Market: Company Product Application Footprint
 Table 50. Nanomaterial-Based Adjuvants Vaccine New Market Entrants and Barriers to Market Entry
 Table 51. Nanomaterial-Based Adjuvants Vaccine Mergers, Acquisition, Agreements, and Collaborations
 Table 52. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
 Table 53. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2019-2024) & (M Doses)
 Table 54. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2025-2030) & (M Doses)
 Table 55. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2024) & (USD Million)
 Table 56. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2025-2030) & (USD Million)
 Table 57. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2019-2024) & (US$/Dose)
 Table 58. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Region (2025-2030) & (US$/Dose)
 Table 59. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
 Table 60. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
 Table 61. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type (2019-2024) & (USD Million)
 Table 62. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Type (2025-2030) & (USD Million)
 Table 63. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2024) & (US$/Dose)
 Table 64. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2025-2030) & (US$/Dose)
 Table 65. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
 Table 66. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
 Table 67. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application (2019-2024) & (USD Million)
 Table 68. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application (2025-2030) & (USD Million)
 Table 69. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2024) & (US$/Dose)
 Table 70. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2025-2030) & (US$/Dose)
 Table 71. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
 Table 72. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
 Table 73. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
 Table 74. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
 Table 75. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
 Table 76. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
 Table 77. North America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 78. North America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 79. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
 Table 80. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
 Table 81. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
 Table 82. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
 Table 83. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
 Table 84. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
 Table 85. Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 86. Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 87. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
 Table 88. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
 Table 89. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
 Table 90. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
 Table 91. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2019-2024) & (M Doses)
 Table 92. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Region (2025-2030) & (M Doses)
 Table 93. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2019-2024) & (USD Million)
 Table 94. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value by Region (2025-2030) & (USD Million)
 Table 95. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
 Table 96. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
 Table 97. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
 Table 98. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
 Table 99. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
 Table 100. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
 Table 101. South America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 102. South America Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 103. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
 Table 104. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
 Table 105. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
 Table 106. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
 Table 107. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
 Table 108. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
 Table 109. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 110. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 111. Nanomaterial-Based Adjuvants Vaccine Raw Material
 Table 112. Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine Raw Materials
 Table 113. Nanomaterial-Based Adjuvants Vaccine Typical Distributors
 Table 114. Nanomaterial-Based Adjuvants Vaccine Typical Customers


List of Figures
 Figure 1. Nanomaterial-Based Adjuvants Vaccine Picture
 Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type in 2023
 Figure 4. Aluminium Hydroxides Examples
 Figure 5. Aluminium Phosphate Examples
 Figure 6. Lipidosome Examples
 Figure 7. Others Examples
 Figure 8. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 9. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application in 2023
 Figure 10. Pneumococcus Examples
 Figure 11. Human Papilloma Virus Examples
 Figure 12. DTaP Examples
 Figure 13. Viral Hepatitis TypeA Examples
 Figure 14. Viral Hepatitis TypeB Examples
 Figure 15. SARS-CoV-2 Examples
 Figure 16. Others Examples
 Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity (2019-2030) & (M Doses)
 Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Price (2019-2030) & (US$/Dose)
 Figure 21. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Manufacturer in 2023
 Figure 22. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturer in 2023
 Figure 23. Producer Shipments of Nanomaterial-Based Adjuvants Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2023
 Figure 24. Top 3 Nanomaterial-Based Adjuvants Vaccine Manufacturer (Revenue) Market Share in 2023
 Figure 25. Top 6 Nanomaterial-Based Adjuvants Vaccine Manufacturer (Revenue) Market Share in 2023
 Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Region (2019-2030)
 Figure 27. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Region (2019-2030)
 Figure 28. North America Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 29. Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 30. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 31. South America Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 32. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 33. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 34. Global Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Type (2019-2030)
 Figure 35. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Type (2019-2030) & (US$/Dose)
 Figure 36. Global Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 37. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2019-2030)
 Figure 38. Global Nanomaterial-Based Adjuvants Vaccine Average Price by Application (2019-2030) & (US$/Dose)
 Figure 39. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 40. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 41. North America Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 42. North America Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 43. United States Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 44. Canada Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 45. Mexico Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 46. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 47. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 48. Europe Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 49. Europe Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 50. Germany Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 51. France Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 52. United Kingdom Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 53. Russia Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 54. Italy Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 55. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 56. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 57. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Region (2019-2030)
 Figure 58. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Region (2019-2030)
 Figure 59. China Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 60. Japan Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 61. South Korea Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 62. India Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 63. Southeast Asia Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 64. Australia Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 65. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 66. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 67. South America Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 68. South America Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 69. Brazil Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 70. Argentina Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 71. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 72. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 73. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 74. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 75. Turkey Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 76. Egypt Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 77. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 78. South Africa Nanomaterial-Based Adjuvants Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 79. Nanomaterial-Based Adjuvants Vaccine Market Drivers
 Figure 80. Nanomaterial-Based Adjuvants Vaccine Market Restraints
 Figure 81. Nanomaterial-Based Adjuvants Vaccine Market Trends
 Figure 82. Porters Five Forces Analysis
 Figure 83. Manufacturing Cost Structure Analysis of Nanomaterial-Based Adjuvants Vaccine in 2023
 Figure 84. Manufacturing Process Analysis of Nanomaterial-Based Adjuvants Vaccine
 Figure 85. Nanomaterial-Based Adjuvants Vaccine Industrial Chain
 Figure 86. Sales Channel: Direct to End-User vs Distributors
 Figure 87. Direct Channel Pros & Cons
 Figure 88. Indirect Channel Pros & Cons
 Figure 89. Methodology
 Figure 90. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Jiangsu Recbio Technology

Related Reports

Global Nanomaterial-Based Adjuvants Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Nanomaterial-Based Adjuvants Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 18 Mar 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Nanomaterial-Based Adjuvants Vaccine market size was valued at USD 60800 million in 2022 and is forecast to a readjusted size of USD 101890 million by 2029 with a CAGR of 7.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Nanomaterial-Based Adjuvants Vaccine Supply, Demand and Key Producers, 2024-2030

Global Nanomaterial-Based Adjuvants Vaccine Supply, Demand and Key Producers, 2024-2030

date 09 Oct 2024

date Pharma & Healthcare

Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.

Product Tags

Nanomaterial-Based Adjuvants Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>